AI-assisted SU•PER•HY•COCK®
The potential of off-label drugs for the advancement of glioblastoma treatment is increasingly recognized. ATCG is developing artificial intelligence-assisted applications to identify combinations of non-oncological drugs (“hard” repurposing) that are tolerable and effective against glioblastoma. Within that concept, a “base” combination is supplemented by a personalized “cap” regimen, with the “cap” drugs targeting molecular alterations present in the individual tumor and the “base” drugs blocking potential compensatory signaling pathways in glioblastoma cells as an add-on intervention (thus “suprapersonalized”). The algorithm hereby balances tolerability and effectivity of the SU•PER•HY•COCK®, applying a proprietary complex set of rules to various specialized databases to extract the required body of information.
